IDE-insulin-Abeta competition

Ide Insulin Abeta Competition enters the Adult Cognitive Disease corpus through the work of Mishauri Nolan (submission 163), and is indexed here as one of the concepts that submission puts to work.

The argument it belongs to

Mishauri Nolan's submission is summarised in this corpus as:

AD is caused by multiple interconnected pathogenic origins requiring combination therapies rather than single-drug approaches. Metabolic dysfunction, particularly insulin resistance and deficient insulin-degrading enzyme (IDE), along with cardiovascular dysfunction and lipid imbalance, converge to drive neurodegeneration. The MEND protocol demonstrates that lifestyle-based multi-target interventions can reverse cognitive decline.

Where it sits

The submission scores against the framework's convergence nodes as: compensatory paradigm 5 · ApoE4 hub 4 · neuroimmune interface 3.

Its declared subject matter: metabolic-dysfunction, insulin-resistance, combination-therapy, MEND-protocol, cardiovascular, lipid-homeostasis, lifestyle-intervention, IDE.

Named by the same submission

3 other concepts enter the corpus through the same paper, so they cover adjacent ground: Lifestyle intervention for cognitive reversal · Metabolic dysfunction as AD driver · Network-based combination therapy.

Assembled from the corpus rather than written: the summary is quoted from the submission that named it; the node scores are read from its dossier. It has not yet been expanded into an article.